| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2021 , Vol 59 , Num 2
Molecular Inclusion -Novel Approach to Enhance Solubility of Olmesartan Medoxomil using Hydroxypropyl β cyclodextrin (HP β-CD)
1 Nagpur college of Pharmacy, Wanadongri, Hingna road, Nagpur2 Department of Pharmaceutical Sciences, R. T. M. Nagpur University, Nagpur, India
DOI : 10.23893/1307-2080.APS.05916 Viewed : 16139 - Downloaded : 3885 Olmesartan medoxomil (OLM) is a BCS Class II anti-hypertensive drug, which is having low aqueous solubility and low bioavailability of 26%. In the present study, the objective of the study was to improve the pharmaceutical limitation of OLM by using Molecular Inclusion Technique. Inclusion complex of OLM with Hydroxypropyl β cyclodextrin (HP β-CD) were prepared in drug/carrier molar ratios of 1:1, 1:2, and 1:3 by Solvent evaporation and Kneading method along with the Physical mixtures. The formation of molecular inclusion complex at 1:2 ratio in the solution was confirmed by Job"s Plot study. The inclusion complex were characterized by Phase solubility study, Fourier transform infrared spectroscopy, Scanning electron microscopy, Differential scanning calorimetry and X-ray diffraction studies. In- vivo pharmacokinetic study reveals enhanced bioavailability of inclusion complexes. Thus, it can be concluded that the formulation of molecular inclusion complex can enhance Solubility and Dissolution making the drug more suitable for treatment. Keywords : Olmesartan medoxomil, Molecular Inclusion, Stability Constant, Dissolution, HP β-CD